0001855485-24-000001.txt : 20240321
0001855485-24-000001.hdr.sgml : 20240321
20240320173207
ACCESSION NUMBER: 0001855485-24-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240320
EFFECTIVENESS DATE: 20240321
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Calidi Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001855485
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 862967193
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-508160
FILM NUMBER: 24768708
BUSINESS ADDRESS:
STREET 1: 4475 EXECUTIVE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-794-9600
MAIL ADDRESS:
STREET 1: 4475 EXECUTIVE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: First Light Acquisition Group, Inc.
DATE OF NAME CHANGE: 20210406
D
1
primary_doc.xml
X0708
D
LIVE
0001855485
Calidi Biotherapeutics, Inc.
4475 EXECUTIVE DRIVE
SUITE 200
SAN DIEGO
CA
CALIFORNIA
92121
858-794-9600
DELAWARE
First Light Acquisition Group, Inc.
Corporation
true
2021
Allan
Camaisa
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Executive Officer
Director
Andrew
Jackson
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Executive Officer
Boris
Minev
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Executive Officer
Wendy
Pizarro
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Executive Officer
Alan
R.
Stewart
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Director
Scott
Leftwich
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Director
George
Ng
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Director
James
A.
Schoeneck
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Director
David
LaPre
4475 Executive Drive, Suite 200
San Diego
CA
CALIFORNIA
92121
Director
Biotechnology
Decline to Disclose
- 06b
false
2024-01-26
false
true
true
true
true
Convertible promissory note and underlying equity upon conversion of convertible promissory note
false
0
1000000
1000000
0
Represents the principal amount of $1,000,000 of a convertible promissory note convertible into equity securities of the issuer.
false
1
0
0
0
false
Calidi Biotherapeutics, Inc.
/s/ Andrew Jackson
Andrew Jackson
Chief Financial Officer
2024-03-20